Progressive Amyloid-Related Imaging Abnormalities After Discontinuation of Lecanemab in Early Alzheimer Disease in an APOE ε2/ε4 Carrier.

Elisabeth Stögmann; Lukas Haider; Joel Leinkauf; Thomas Nakuz; Helena Untersteiner; Clemens Farr; Sara Silvaieh; Tandis Parvizi; Raphael Wurm; Gregor Kasprian; Thomas Berger; Ellen Gelpi; Evelyn Berger Sieczkowski

doi:10.1111/ene.70779

SCHEDA SCIENTIFICA2026Caso clinico

Progressive Amyloid-Related Imaging Abnormalities After Discontinuation of Lecanemab in Early Alzheimer Disease in an APOE ε2/ε4 Carrier.

Elisabeth Stögmann, Lukas Haider, Joel Leinkauf, Thomas Nakuz, Helena Untersteiner, Clemens Farr, Sara Silvaieh, Tandis Parvizi, Raphael Wurm, Gregor Kasprian, Thomas Berger, Ellen Gelpi, Evelyn Berger Sieczkowski

European journal of neurology · 2026

Psicologia clinica Psicoterapia

Abstract e pubblicazione originale

L’abstract è consultabile nella fonte originale. Non viene ripubblicato qui perché non risulta verificata una licenza compatibile.

Leggi nella fonte originale ↗

Parole chiave

HumansAlzheimer DiseaseAntibodies, Monoclonal, HumanizedApolipoprotein E2Apolipoprotein E4BrainDisease ProgressionHeterozygoteMagnetic Resonance ImagingAPOE ε2/ε4ARIAAlzheimer's diseasecerebral amyloid angiopathylecanemab

Come citare questo studio

Elisabeth Stögmann, Lukas Haider, Joel Leinkauf, Thomas Nakuz, Helena Untersteiner, Clemens Farr, Sara Silvaieh, Tandis Parvizi, Raphael Wurm, Gregor Kasprian, Thomas Berger, Ellen Gelpi, Evelyn Berger Sieczkowski. (2026). Progressive Amyloid-Related Imaging Abnormalities After Discontinuation of Lecanemab in Early Alzheimer Disease in an APOE ε2/ε4 Carrier.. European journal of neurology. DOI: 10.1111/ene.70779

Consulta la pubblicazione originale ↗